Pacific Edge (NZSE:PEB) - Prezzo delle azioni, notizie e analisi

PEB Panoramica delle azioni

PEB analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Non ha una capitalizzazione di mercato significativa ( NZ$112M )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Pacific Edge Limited Concorrenti

AFT Pharmaceuticals

NZSE:AFT

NZ$274.7m

PYC Therapeutics

ASX:PYC

AU$853.9m

DBV Technologies

ENXTPA:DBV

€49.2m

Eutilex.Co.Ltd

KOSDAQ:A263050

₩73.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Pacific Edge
Prezzi storici delle azioni
Prezzo attuale dell'azione	NZ$0.14
Massimo di 52 settimane	NZ$0.18
Minimo di 52 settimane	NZ$0.071
Beta	1
1Variazione di 1 mese	0.71%
Variazione a 3 mesi	40.59%
Variazione di 1 anno	40.59%
3Variazione a 3 anni	-89.08%
Variazione a 5 anni	3.65%
Variazione dall'IPO	-18.86%

Notizie e aggiornamenti recenti

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Nov 15

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Sep 16

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Aug 16

Recent updates

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Nov 15

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Sep 16

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Dec 18

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Jun 06

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

May 27

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

May 23

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Sep 06

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

May 31

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Jan 17

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Jun 05

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

May 14

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Mar 21

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Mar 13

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Feb 14

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Jan 18

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

Dec 23

Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?

Nov 21

Rendimenti per gli azionisti

	PEB	NZ Biotechs	NZ Mercato
7D	1.4%	-3.7%	0.1%
1Y	40.6%	10.0%	9.6%

Ritorno vs Industria: PEB ha superato il NZ Biotechs che ha restituito 10 % nell'ultimo anno.

Rendimento vs Mercato: PEB ha superato il mercato NZ che ha restituito 9.6 % nell'ultimo anno.

Volatilità dei prezzi

Is PEB's price volatile compared to industry and market?
PEB volatility
PEB Average Weekly Movement	11.7%
Biotechs Industry Average Movement	9.9%
Market Average Movement	4.5%
10% most volatile stocks in NZ Market	9.3%
10% least volatile stocks in NZ Market	3.0%

Prezzo delle azioni stabile: Il prezzo delle azioni di PEB è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 12% ) di PEB è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni NZ.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	114	Peter Meintjes	www.pacificedgedx.com

Pacific Edge Limited, società di diagnostica oncologica, ricerca, sviluppa e commercializza strumenti diagnostici e prognostici per la diagnosi precoce e la gestione dei tumori in Nuova Zelanda, negli Stati Uniti e a livello internazionale. Opera attraverso due segmenti: commerciale e di ricerca. L'azienda offre Cxbladder, un test genomico di biomarcatori delle urine per la rilevazione e la sorveglianza del cancro alla vescica.

Pacific Edge Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Pacific Edge con la sua capitalizzazione di mercato?
PEB statistiche fondamentali
Capitalizzazione di mercato	NZ$112.04m
Guadagni(TTM)	-NZ$29.53m
Ricavi(TTM)	NZ$25.23m

4.6x

Rapporto P/S

-3.9x

Rapporto P/E

PEB è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PEB Conto economico (TTM)
Ricavi	NZ$25.23m
Costo del fatturato	NZ$11.75m
Profitto lordo	NZ$13.48m
Altre spese	NZ$43.01m
Guadagni	-NZ$29.53m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

Nov 25, 2024

Utile per azione (EPS)	-0.036
Margine lordo	53.42%
Margine di profitto netto	-117.07%
Rapporto debito/patrimonio netto	0.5%

Come si è comportato PEB nel lungo periodo?

Vedi performance storica e confronto

PEB Panoramica delle azioni

Analisi del rischio

Pacific Edge Limited Concorrenti

NZSE:AFT

NZ$274.7m

ASX:PYC

AU$853.9m

ENXTPA:DBV

€49.2m

KOSDAQ:A263050

₩73.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024

Price target increased by 19% to NZ$0.15

New major risk - Share price stability

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Recent updates

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024

Price target increased by 19% to NZ$0.15

New major risk - Share price stability

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Consensus EPS estimates upgraded to NZ$0.034 loss

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Price target decreased by 7.8% to NZ$0.15

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

Consensus forecasts updated

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Price target decreased to NZ$0.61

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Price target decreased to NZ$0.72

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Consensus revenue estimates fall by 27%

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

Now 26% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NZ$1.11

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Consensus forecasts updated

Price target decreased to NZ$1.32

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Insufficient new directors

Consensus revenue estimates fall to NZ$12.9m

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

CEO, MD & Executive Director exercised options to buy NZ$478k worth of stock.

Consensus EPS estimates fall to -NZ$0.014

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Full year 2021 earnings released: NZ$0.02 loss per share (vs NZ$0.032 loss in FY 2020)

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Insider recently sold NZ$130k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Insider recently sold NZ$120k worth of stock

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?